New Developments in Dual-Labeled Molecular Imaging Agents

Area of Science:

• Surgical Oncology
• Molecular Imaging
• Biomedical Engineering

Background:

• Intraoperative tumor detection is crucial for surgical oncology, addressing unmet needs in cancer surgery.
• Current methods rely on visual and tactile guidance, often supplemented by fluorescent contrast agents.
• Limitations exist in precisely identifying tumor deposits, margins, and residual cancer.

Purpose of the Study:

• To review novel strategies for developing and evaluating targeted dual-labeled molecular imaging agents.
• To highlight the integration of fluorescent and nuclear imaging for enhanced intraoperative visualization.
• To discuss the first-in-human application of this multimodality approach.

Main Methods:

• Development of targeted molecular imaging agents with dual fluorescent and nuclear labels.
• Evaluation of these agents for intraoperative imaging during surgical procedures.
• Analysis of the combined capabilities for precise tumor detection and margin assessment.

Main Results:

• Successful development of multimodality agents combining fluorescent and nuclear contrast.
• Demonstration of enhanced intraoperative imaging beyond visual and tactile guidance.
• Successful first-in-human application validating the technique's potential.

Conclusions:

• Targeted dual-labeled molecular imaging agents represent a significant advancement in surgical oncology.
• The combination of fluorescent and nuclear imaging offers quantitative, noninvasive capabilities for intraoperative assessment.
• This multimodality approach promises to improve surgical outcomes by enhancing tumor detection and margin control.